✦ LIBER ✦

Erlotinib dominates docetaxel for NSCLC

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF TH

✍ M Pompen; A Novak; P Postmus; M Gok; M Gyldmark 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Bevacizumab + erlotinib promising for NS

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB

Erlotinib approved in Switzerland for NS

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Sequential cisplatin/gemcitabine, doceta

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Lung cancer: OPTIMAL results for erlotin

✍ Hutchinson, Lisa 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 46 KB

NICE issues erlotinib guidance for use i

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB